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INTRODUCTION: Isolated splenic metastasis are very rare. There are only a few reported cases of patients
with isolated splenic metastasis from gastric primary tumors.
PRESENTATION OF CASE: Wepresent a case of a 71-year-old patientwith isolated splenicmetastasis, diag-
nosed 6 years after primary treatment of a gastric adenocarcinoma, who previously had a lung resection
also for metastasis. The patient was submitted to chemotherapy and then to splenectomy. The patient is
alive and has no evidence of disease 7 months after splenectomy.
DISCUSSION: Wediscuss the theories that explain the rare event of splenicmetastasis, the route ofmetas-
tization, the workup, treatment and survival of patients with isolated splenic metastasis. To the best of
our knowledge, our case has the second longest interval from the primary diagnosis of gastric cancer to
the diagnosis of splenic metastasis.
CONCLUSION: In cases of isolated splenic metastasis from gastric adenocarcinoma, ﬁt patients should be
considered for splenectomy, since there are reports of good patient survivals.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Splenic metastasis are uncommon.1–4 The largest studies on
autopsy reports from patients with non-haematogenous tumors,
stated a 0.3–7.3% rate of splenic metastasis.2 In most cases, this
happens as part of disseminated multi-organ disease.
The most frequent primary tumors metastasizing to the spleen
are breast, lung, ovary, colorectal, skin and gastric.1–3,5 The latter
are reported with an incidence of 6.9%.2
Isolated splenic metastasis are very rare, with only a few
reported cases of patients with primary gastric tumors.6
The authors present a case of a patient with isolated splenic
metastasis from primary gastric adenocarcinoma.
2. Presentation of case
A 71-year-old man underwent a total gastrectomy with D2
lymphadenectomy and Y-Roux reconstruction for a distal small
curvature gastric cancer, in 2005. Histologic report conﬁrmed a
well differentiated adenocarcinoma, Laurens’s intestinal type and
28non-metastasized lymphnodes–ﬁnal stagingpT3N0M0.Hewas
not proposed to chemotherapy.
After 6 years of follow-up, it was noted an elevated CA19.9, with
normal CEA (Graphic 1 – June/2011). Computerized tomography
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(CT) scan revealed an isolated nodular lesion on the left superior
lobe of the lung (Fig. 1). After two attempts of percutaneous biopsy
(both yielded insufﬁcient tissue), it was decided to proceed with
surgical excision. On December/2011 he was submitted to a left
superior lobectomy. Histology conﬁrmed a gastric adenocarcinoma
metastasis with complete excision.
Three months after the pulmonary surgery, the patient pre-
sented an even greater rise of CA19.9 (Graphic 1 – March/2012).
CT scan showed a splenic formation with undetermined mean-
ing. At this point it was decided to perform a positron emission
tomography–computed tomography (PET–CT) scanwhich revealed
two active spots – one on the left lung related to the previ-
ous surgery (a false-positive) and the other one on the spleen
(Fig. 2).7,8 On Oncology Group (OG) discussion, these ﬁndings were
Graphic 1. Tumoral markers evolution since Jan/2010, 6 years after the primary
gastric surgery.
http://dx.doi.org/10.1016/j.ijscr.2014.10.094
2210-2612/© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Image of CT scan showing a pulmonary nodule, with 28×19mm, speculated
and irregular, suspected of metastasis.
interpreted as disseminated disease and it was proposed palliative
chemotherapy.
After 6 cycles of epirubicin, oxaliplatin and capecitabine (EOX),
which terminated on October/2012, CA19.9 normalized and the
patient remained asymptomatic. The OG decided to keep a sup-
portive treatment.
On April/2013 the patient had another CA 19.9 elevation with
an 18mm splenic lesion on CT scan, compatible with previously
diagnosed metastasis.
On August/2013 the patient remained asymptomatic although
the splenic lesion grew to 25mm (Fig. 3), with no evidence of other
metastasis.
The apparently indolent evolution of the disease and the good
physiologic status of the patient, promoted the OG decision to per-
form splenectomy.
The surgery was performed on the 21/November/2013. Intra-
operatively it was seen a hard nodule on the inferior pole of the
spleen, with extension to the hilum. No other lesions were noted.
The post-operative period was uneventful and the patient was dis-
charged at the 4th day after surgery.
The pathological examination conﬁrmed the presence of a
25×15×10mm nodule, with hilar and capsule invasion, with
histological morphology of an adenocarcinoma. After immuno-
histochemical study and pathological comparative review of the
primary carcinoma, the lesion was deemed most likely to be a gas-
tric adenocarcinoma metastasis (Figs. 4 and 5). There were two
othermetastatic nodules,with 15 and10mm, located in the splenic
parenchyma, independent from the ﬁrst nodule and with no cap-
sule invasion.
Again, he was proposed chemotherapy with EOX.
At present, the patient is receiving chemotherapy with very
good tolerance and has no evidence of disease.
3. Discussion
From the early 20th century there have been explanations stat-
ing that there are obstacles preventing tumoral cells from reaching
the spleen. These include the sharp angle of the splenic artery with
the celiac trunkand the rhythmic contractionof splenic sinusoidals.
As we know from present knowledge, the success of metastization
seems to be much more dependent on the local microenvironment
on which the tumoral cells lodge, and the interactions between
them.9 The spleen seems to be hostile to the growing of clinical
metastasis, probably related to its immune function. For 6 years
our patient had “dormant” cells or micrometastasis that suddenly
started to grow. To the best of our knowledge, our case has the sec-
ond longest interval from the primary diagnosis of gastric cancer
to the diagnosis of splenic metastasis.6,10
The usual suggested route of metastization is hematogeneous
related to parenchymal location of the metastasis and no capsule
invasion. On our case, there were two small parenchymal metasta-
siswith no capsule invasion, but the biggestmetastasis had capsule
Fig. 2. Image of PET-CT showing a splenic hot spot, suspect of metastasis.
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Fig. 3. Image of CT scan showing a 25mm splenic lesion, near its inferior pole, compatible with metastasis.
Fig. 4. H&E 40× and 100× – moderately differentiated adenocarcinoma, inﬁltrating the splenic parenchyma and inducing a mild desmoplastic and inﬂammatory reaction.
Fig. 5. CK 7 and CK 20, 400× – immunohistochemical studies for cytokeratins 7 and 20 showed expression of cytokeratin 7 and no expression of cytokeratin 20. This
immunoproﬁle is coincident with the primary gastric tumor proﬁle suggesting the gastric origin of this metastasis.
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invasion. Despite this, the hematogeneous route is the most prob-
able since there were no lymph nodes involved at the primary
surgery and there was no peritoneal seeding.
Some reported cases of isolated splenic metastasis, seem to be
part of aggressive loco-regional advanced disease with great prob-
ability of being a fully disseminated disease not recognized at that
point. These cases are mostly seen on upper third gastric tumors,
locally advanced tumors, with extensive nodal involvement, and
invariably short survival.6
Most patients are asymptomatic. The symptoms and signs most
frequently reported are asthenia, weight loss, abdominal pain,
anemia and splenomegaly.4 There are cases of splenic abscess for-
mation or rupture as initial presentation.2,11
Most diagnosis are dependent on imaging. Ultrasound and CT
scan are the usual performed exams during follow-up whenever
indicated by symptoms or elevation of CEA and CA 19.9.12 At some
instances, there is doubt about the nature of lesions. PET-CT scan
might be very useful since it has a high negative predictive value
considering malignant lesions and it might show other probable
metastatic spots not detected on CT scan.7,8
A true pre-operative diagnosis of splenic metastasis can only be
made through biopsy. Although it is rarely described, it is consid-
eredboth safe and reliablewhenevaluating splenic lesions.13,14 Our
patient was not submitted to biopsy since there was a good corre-
lation between CT and PET-CT scan suspicion, lesion evolution and
tumoral markers. The diagnosis of metastasis was highly probable.
We recommend biopsy on less clear cases.
On reported cases of isolated splenic metastasis, as long as the
patients are ﬁt, they get treated by splenectomy with or without
chemotherapy.6,12,15
Chemotherapy varies from neoadjuvant to adjuvant settings,
multidrug or monodrug regimens. There are not consensual pro-
tocols. Our patient had multidrug chemotherapy with EOX which
are ﬁrst line drugs on National Comprehensive Cancer Network
guidelines.
Our case is remarkable because our patient had a resected pul-
monary metastasis prior to the splenic metastasis diagnosis. The
high probability of having multi-organ disseminated disease was
the rationale for the decision to perform palliative chemother-
apy and then supportive treatment only. With time, the patient
proved he was a great candidate for surgery, since no other metas-
tasis grew. This “wait-and-see” approach has been defended as a
way of selecting patients that truly beneﬁt from aggressive surgical
treatment.6,15 Overall, the reported cases do not mention relevant
complications from splenectomy in this setting.
The reported overall survivals point an advantage if the metas-
tasis are diagnosed within a medium to long follow-up. Patients
who had long free disease survivals are also the ones with longest
overall survival.6,10
4. Conclusion
In cases of isolated splenic metastasis from gastric adenocar-
cinoma, ﬁt patients should be considered for splenectomy, since
there are reports of good patient survivals.3,6,10
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Key learning points
• Splenic metastasis are rare.
• Surgery should be considered for selected patients as a way of improving survival.
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